HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.
August 11, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $12.
The reiteration of a 'Buy' rating and a maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock's demand and subsequently its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100